Ultralife Corp (ULBI)
NASDAQIndustrialsElectrical Equipment & PartsSnapshot 2026-07-23
Reading ULBI? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →NASDAQIndustrialsElectrical Equipment & PartsSnapshot 2026-07-23
Reading ULBI? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a turnaround situation with a focus on restoring profitability. The current thesis state indicates that while management is stable, recent financial performance has been weak, leading to a cautious outlook.
The valuation suggests that ULBI is considered cheap compared to its peers, with a notable expectations gap. The market seems to have priced in some level of fragility, but it has not yet reacted strongly to recent earnings misses.
Fundamentals are likely to remain under pressure given the company's ongoing losses and the elevated risk of another earnings miss. Management's focus on restoring profitability and generating cash flow has not yet shown significant progress.
The long-term thesis hinges on the performance of sector bellwethers like VRT, BE, and NVT. If these companies continue to perform well, it could provide a tailwind for ULBI, but any negative guidance from them could further challenge ULBI's prospects.
In the 1-3 year view, ULBI's path forward is uncertain, heavily influenced by sector dynamics and management execution. Not investment advice.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. The primary driver is a sharp drop in ULBI's stock price, which suggests the market may be repricing the reasons to own the company. This decline of 18% from its recent high indicates concerns about its financial performance, which remains below industry standards.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: Investing in capital is key for Ultralife's growth. Updates can show future success.
Confirms one read:Management shares a new plan for capital spending with clear goals.
Confirms the other:Management has not shared updates. They have not delayed their planned spending.
Why it matters: If revenue growth speeds up, it may signal a turnaround for the company. This could change investor views.
Confirms:Revenue growth returns to above 5% year over year.
Disproves:Revenue growth remains below 5% year over year.
Why it matters: This report will show if Ultralife is moving toward profitability. A strong report could boost investor confidence.
Confirms:Q2 earnings report shows a net income improvement compared to -$451,000 in Q1.
Disproves:Q2 earnings report shows a net loss equal to or worse than -$451,000.
Why it matters: Management aims to restore profitability and generate cash flow. Progress here is crucial for future growth.
Confirms:Management says cash flow from operations will be positive in the next quarters.
Disproves:Continued negative cash flow reported in the next two quarters.
Why it matters: Improving cash flow is important for Ultralife. It helps the company make more money.
Confirms:Q2 cash flow from operations turns positive after a negative cash flow in Q1.
Disproves:Q2 cash flow from operations remains negative.
Why it matters: A growing backlog means strong future sales for Ultralife's products. This could help make more money.
Confirms:Backlog increases to over $120 million by the next earnings report.
Disproves:If the backlog goes down or stays below $115 million, it suggests weak demand.